product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
Phospho-PRAS40 (Thr246) (D4D2) XP Rabbit mAb
catalog :
13175
clonality :
monoclonal
host :
domestic rabbit
conjugate :
nonconjugated
clone name :
D4D2
reactivity :
human, mouse
application :
western blot
more info or order :
Cell Signaling Technology product webpage
citations: 9
Published Application/Species/Sample/DilutionReference
  • western blot; human; 1:1000; loading ...; fig 2a
  • western blot; mouse; 1:1000; loading ...; fig 2b
VASAN N, Razavi P, Johnson J, Shao H, Shah H, Antoine A, et al. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. Science. 2019;366:714-723 pubmed publisher
  • western blot; human; loading ...; fig 4f
Gioran A, Piazzesi A, Bertan F, Schroer J, Wischhof L, Nicotera P, et al. Multi-omics identify xanthine as a pro-survival metabolite for nematodes with mitochondrial dysfunction. EMBO J. 2019;38: pubmed publisher
  • western blot; human; loading ...; fig 4a
Bishnupuri K, Alvarado D, Khouri A, Shabsovich M, Chen B, Dieckgraefe B, et al. IDO1 and kynurenine pathway metabolites activate PI3K-Akt signaling in the neoplastic colon epithelium to promote cancer cell proliferation and inhibit apoptosis. Cancer Res. 2019;: pubmed publisher
  • western blot; human; 1:1000; loading ...; fig 1e
Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359:920-926 pubmed publisher
  • western blot; human; loading ...; fig 2c
Bostner J, Alayev A, Berman A, Fornander T, Nordenskjold B, Holz M, et al. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2018;168:17-27 pubmed publisher
  • western blot; human; loading ...; fig 2a
Mondello P, Derenzini E, Asgari Z, Philip J, Brea E, SESHAN V, et al. Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. Oncotarget. 2017;8:14017-14028 pubmed publisher
  • western blot; human; loading ...; fig s6
Mirkheshti N, Park S, Jiang S, Cropper J, Werner S, Song C, et al. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer. Oncotarget. 2016;7:62240-62254 pubmed publisher
  • western blot; human; 1:1000; loading ...; fig 4.a, b, c
Maynard J, Emmas S, Blé F, Barjat H, Lawrie E, Hancox U, et al. The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3K?/? inhibitor. EJNMMI Res. 2016;6:62 pubmed publisher
  • western blot; human; 1:1000; fig 4b
Sadowski S, Boufraqech M, Zhang L, Mehta A, Kapur P, Zhang Y, et al. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis. Oncotarget. 2015;6:18038-49 pubmed
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
https://www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.